Question to the Department of Health and Social Care:
To ask Her Majesty's Government what plans they have to evaluate AZD7442 for emergency use as a preventative treatment against COVID-19; and what are the timelines for its approval.
We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442. AstraZeneca are discussing potential approval for the therapy with the Medicines and Healthcare products Regulatory Agency.
We anticipate that further neutralising monoclonal antibody treatments will be submitted for evaluation for a marketing authorisation by the MHRA in the next few months. These treatments could become available for community treatment or preventative use.